text_1: MEK inhibitors are effective treatments in RAS-driven mouse models of cancer.
text_2: These in vivo studies suggest that inhibitors of the PI3K-mTOR pathway may be active in cancers with PIK3CA mutations and, when combined with MEK inhibitors, may effectively treat KRAS mutated lung cancers.